Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 4, 2008, Pages 199-205

  Yamamoto, Takeshi ^a   Hirano, Tsutomu ^a   Mori, Yusaku ^a   Tokuno, Anna ^a   Nagashima, Masaharu ^a   Takada, Michiya ^a   Morita, Ryo ^a   Lee, Soushou ^a   Hayashi, Toshiyuki ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein B48; Diabetic nephropathy; Postprandial lipemia; Small dense LDL

Indexed keywords

EID: 56349091903     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E558     Document Type: Article

References (29)

1. United States Renal Data System: USRDS 1998 annual data report, excerpts from V and VI, J Kidney Dis, 1998; 2 (Suppl 1):69-80, 81-88
2. Hahn R, Oette K, Mondorf H, Finke K, and Sieberth HG: Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis, 1983;48:279-288
3. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, and Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int, 2000;58:353-362
4. Valmadrid CT, Klein R, Moss SE, and Klein BE: The risk of cardiovascular diseas mortality associated with micro-albuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med, 2000;160:1093-1100
5. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, and Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure, Nephrol Dial Transplant, 1998;13:2833-2841
6. Hirano T: Lipoprotein abnormalities in diabetic nephropathy, Kidney Int Suppl, 1999;71:S22-S24
7. Jensen T, Borch-Johnsen K. Kofoed-Envoldsen A, and Deckert T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy, incidence and risk factors. Diabetologia, 1987;30:144-148
8. De Cosmo S, Bacci S, Piras GF, Cignarelli M, Placentino G, Margaglione M, Colaizzo D, Minno G. Giorgino R, Liuzzi A, and Viberti GC: High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria, Diabetologia, 1997;40:1191-1196
9. Kashiwazaki K, Hirano T, Yoshino G, Kurokawa M, Tajima H, and Adachi M: Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diabetes Care, 1998:21:2016-2020
10. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T. Okada K, Takeuchi H, Yoshino G, and Adachi M: Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII, Kidney Int, 2003;63:2171-2177
11. Wilhelm MG and Cooper AD: Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb, 2003;10:132-139
12. Proctor SD, Vine DF, and Mamo JC: Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confacal microscopy. Arterioscler Thromb Vasc Biol, 2004;24:2162-2167.
13. Proctor SD and Mamo JC: Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48- containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol, 2003;23:1595-1600
14. Pal S, Semorine K, Watts GF. and Mamo J: Identification of lipoproteins of intestinal origin in human atherosclerotic plaque, Clin Chem Lab Med, 2003; 41:792-795
15. Redgrave TG: Chylomicron metabolism, Biochem Soc Trans, 2004; 32:79-82
16. Brown ML, Ramprasad MP, Umeda PK, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo WL, Li R, Song R, Bladley WA, and Gianturco SH: A macrophage receptor for apolipoprotein B48: cloning, expression and atherosclerosis, Proc Natl Acad Sci USA, 2000; 97:7488-7493
17. Flood C, Gustafson M, Richardson PE, Harvey SC, Segrest JP, and Borén J: Identification of the proteoglycan binding site in apolipoprotein B48, J Biol Chem, 2002; 277:32228-32233
18. Hirano T, Oi K, Sakai S, Kashiwazaki K, Adachi M, and Yoshino G: High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia, Atherosclerosis, 1998; 141:77-85
19. Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, and Adachi M: Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease, Atherosclcrosis 2008; 197:154-158
20. Yoshino G, Tominaga M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, and Tachikawa T: The Test Meal A: A Pilot Model for the International Standard of Test Meal for an Assessment of Both Pöstprandial Hyperglycemia and Hyperlipidemia, Journal of the Japan Diabetes Society, 2006; 49:361-372
21. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, Kihara S, Hiraoka H, Nakamura T, Ito S, Yamashita S, and Matsuzawa Y: Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA, J Lipid Res, 2003, 44:1256-1262
22. Hirano T, Ito Y, and Yoshino G, Measurement of small dense low-def1sity lipoprotein particles, J Atheroscler Thromb, 2005; 12:67-72
23. Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou EC, Tselepis AD, and Katsilambros N: High postprandial triglyceridemia in patients with. type 2 diabetes and microalbuminuria, J Lipid Res, 2007; 48:218-225
24. Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism, Curr Opin Lipidol, 2001; 12:297-304
25. Dichek HL, Qian K, and Agrawal N: The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient "apoB-48-only" and "apoB-100-only" mice. J Lipid Res, 2004;45:551-560
26. Oi K, Hirano T, Sakai S, Kawaguchi Y, and Hosoya T: Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl, 1999; 71:227-228
27. Taskinen MR: Insulin resistance and lipoprotein metabolism, Curr Opin Lipidol, 1995; 6:153-160
28. Valero R, Lorec AM, Paganelli F, Beliard S, Atlan C, Lairon D, Vialettes B, and Portugal H: Fasting apoprotein B48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia, Metabolism, 2005; 54:1442-1447
29. Kaèpe F, Steiner G, Uffelman K, Olivecrona T, and Hamsten A: Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis, 1994; 106:83-97